

## International multicentre study confirms accuracy and clinical usefulness of FerriScan® R2-MRI

Resonance Health is pleased to announce the peer reviewed publication of a significant validation study for FerriScan R2-MRI.

*Multicenter validation of spin-density projection-assisted R2-MRI for the non-invasive measurement of liver iron concentration* (Tim G. St Pierre, et al ) is published in Magnetic Resonance in Medicine. Click [here](#) for access to the full paper. The study was conducted on a group of 233 thalassaemia patients ranging from three years of age at 5 international clinical centres.

FerriScan R2-MRI has gained international acknowledgement as the gold standard for non-invasive MRI measurement of liver iron concentration. This is now further substantiated by the publication of a paper demonstrating that the technology can be used in different MRI centres on different makes and models of scanners with no impact on the accuracy of the liver iron concentration result.

The study also showed that FerriScan's accuracy is unaffected by the degree of liver fibrosis, the age of the patient, and the use of the drug deferasirox thus confirming its clinical usefulness in monitoring body iron load during iron chelation therapy.

FerriScan R2-MRI is provided to the clinical community by Resonance Health's central image analysis laboratory in Perth, Western Australia. FerriScan R2-MRI has clearance from the FDA, TGA and other regulatory authorities and carries the CE mark in Europe. It is used in many hospitals around the world for measurement of liver iron concentration in patients who are at risk of liver iron overload. Liver iron overload is incurred through chronic blood transfusions required in the treatment of diseases such as thalassaemia, sickle cell disease and myelodysplastic syndrome.

Clinicians managing iron chelation therapy in these patients require a safe and accurate method of measuring body iron overload. As a result, FerriScan R2-MRI has now been included in many international guidelines and protocols developed by clinicians specialising in the treatment of iron-loading conditions.

This publication sets new standards in validating accuracy of non-invasive technology for assessing tissue iron.

For further information please contact:

**Resonance Health**

Liza Dunne

Managing Director

T: +61 8 9286 5300

E: lizad@resonancehealth.com

Naomi Haydari

Company Secretary

T: +61 8 9286 5300

E: naomih@resonancehealth.com

Resonance Health Ltd (ASX: RHT) ([www.resonancehealth.com](http://www.resonancehealth.com)) is a medical device company providing imaging core laboratory services for the quantitative analysis of medical images, with a subspecialty in the liver. Resonance Health's patented FerriScan technology provides a safe and accurate alternative for measuring liver iron concentration, and research continues into the development of new technology for the accurate assessment of liver fat and liver fibrosis.